ArriVent BioPharma (ArriVent BioPharma) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ArriVent BioPharma's Free Cash Flow for the three months ended in Mar. 2024 was $-18.63 Mil. ArriVent BioPharma's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, ArriVent BioPharma's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, ArriVent BioPharma's current FCF Yield % is -8.84%.

The historical rank and industry rank for ArriVent BioPharma's FCF Margin % or its related term are showing as below:

AVBP's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.31
* Ranked among companies with meaningful FCF Margin % only.

ArriVent BioPharma FCF Margin % Historical Data

The historical data trend for ArriVent BioPharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma FCF Margin % Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

ArriVent BioPharma Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of ArriVent BioPharma's FCF Margin %

For the Biotechnology subindustry, ArriVent BioPharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ArriVent BioPharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's FCF Margin % falls into.

ArriVent BioPharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ArriVent BioPharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-55.842	/	0
	=	%

ArriVent BioPharma's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-18.628	/	0
	=	%

ArriVent BioPharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma (ArriVent BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. They seek to utilize our team's deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

ArriVent BioPharma (ArriVent BioPharma) Headlines

From GuruFocus

ArriVent Appoints Kristine Peterson to its Board of Directors

By Marketwired • 04-22-2024